Audentes Therapeutics Inc (BOLD) Shares Bought by Geode Capital Management LLC
Geode Capital Management LLC raised its stake in Audentes Therapeutics Inc (NASDAQ:BOLD) by 16.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 394,455 shares of the biotechnology company’s stock after acquiring an additional 56,856 shares during the quarter. Geode Capital Management LLC owned approximately 0.92% of Audentes Therapeutics worth $8,409,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. BB Biotech AG purchased a new position in Audentes Therapeutics in the fourth quarter valued at about $16,404,000. Dimensional Fund Advisors LP purchased a new position in Audentes Therapeutics in the third quarter valued at about $6,708,000. Assenagon Asset Management S.A. purchased a new position in Audentes Therapeutics in the fourth quarter valued at about $1,539,000. Artal Group S.A. boosted its stake in Audentes Therapeutics by 140.0% in the fourth quarter. Artal Group S.A. now owns 600,000 shares of the biotechnology company’s stock valued at $12,792,000 after acquiring an additional 350,000 shares during the last quarter. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its stake in Audentes Therapeutics by 46.1% in the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 6,280 shares of the biotechnology company’s stock valued at $138,000 after acquiring an additional 1,983 shares during the last quarter.
A number of research firms have weighed in on BOLD. HC Wainwright reiterated a “buy” rating and issued a $44.00 target price (up from $33.00) on shares of Audentes Therapeutics in a research note on Monday, March 18th. William Blair reiterated a “hold” rating on shares of Audentes Therapeutics in a research note on Wednesday, February 27th. ValuEngine upgraded shares of Audentes Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Monday, April 1st. Zacks Investment Research upgraded shares of Audentes Therapeutics from a “hold” rating to a “buy” rating and set a $28.00 target price on the stock in a research note on Tuesday, January 8th. Finally, Piper Jaffray Companies boosted their target price on shares of Audentes Therapeutics from $45.00 to $55.00 and gave the company a “positive” rating in a research note on Monday, April 8th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $37.08.
Audentes Therapeutics (NASDAQ:BOLD) last announced its quarterly earnings results on Wednesday, February 27th. The biotechnology company reported ($0.84) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.92) by $0.08. During the same quarter in the previous year, the firm earned ($0.82) EPS. On average, sell-side analysts forecast that Audentes Therapeutics Inc will post -3.83 earnings per share for the current year.
In related news, Director Louis G. Lange sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, March 25th. The shares were sold at an average price of $36.00, for a total transaction of $720,000.00. Following the sale, the director now directly owns 306,099 shares in the company, valued at approximately $11,019,564. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Matthew R. Patterson sold 21,000 shares of the company’s stock in a transaction that occurred on Monday, February 25th. The shares were sold at an average price of $30.00, for a total transaction of $630,000.00. Following the sale, the chief executive officer now owns 135,700 shares in the company, valued at $4,071,000. The disclosure for this sale can be found here. Insiders have sold a total of 51,000 shares of company stock worth $1,650,600 over the last 90 days. 6.60% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.dailypolitical.com/2019/04/16/audentes-therapeutics-inc-bold-shares-bought-by-geode-capital-management-llc.html.
About Audentes Therapeutics
Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.
Featured Article: Average Daily Trade Volume – ADTV
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.